CFDE Data Portal | Search LINC01873

	Label	Description
	LINC01873 Gene (Entity type)	ENSG00000232164 - long intergenic non-protein coding RNA 1873
	GSE113655 phenol 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE162892 ISOX 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE73573 KDM1B knockdown 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE205714 GSE229013 adenosine 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE101754 FXR1 knockdown NCI-H358 5 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE100148 EZH2 inhibition 4 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE130437 palbociclib 2 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 5 v 4 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 paclitaxel 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

LINC01873

ENSG00000232164 - long intergenic non-protein coding RNA 1873

GSE113655 phenol 1 v 2 human dn

A Gene Set from LINCS

GSE162892 ISOX 3 v 2 human dn

A Gene Set from LINCS

GSE73573 KDM1B knockdown 1 v 0 human dn

A Gene Set from LINCS

GSE205714 GSE229013 adenosine 3 v 2 human dn

A Gene Set from LINCS

GSE101754 FXR1 knockdown NCI-H358 5 v 2 human dn

A Gene Set from LINCS

GSE100148 EZH2 inhibition 4 v 5 human dn

A Gene Set from LINCS

GSE130437 palbociclib 2 v 3 human dn

A Gene Set from LINCS

GSE113655 phenol 5 v 4 human dn

A Gene Set from LINCS

GSE172016 paclitaxel 2 v 1 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.